Effect of Repetitive Transcranial Magnetic Stimulation approved by FDA (rTMS-FDA) versus Repetitive Transcranial Magnetic Stimulation with concentration on Mirror Neuron System (rTMS-MNS) on emotion and mood regulation in patients with major depressive disorder

Effect of Repetitive Transcranial Magnetic Stimulation approved by FDA (rTMS-FDA) versus Repetitive Transcranial Magnetic Stimulation with concentration on Mirror Neuron System (rTMS-MNS) on emotion and mood regulation in patients with major depressive disorder: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201610209014N123

Enrollment

Registered

2016-10-29

Start date

2016-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depression. Severe depressive episode with psychotic symptoms

Interventions

Intervention 1: Intervention group: Transcranial Magnetic Stimulation approved by FDA for 30 minutes 5 times a week for 2 consecutive weeks. Intervention 2: Control group: Transcranial Magnetic Stimul

Treatment - Other

Intervention group: Transcranial Magnetic Stimulation approved by FDA for 30 minutes 5 times a week for 2 consecutive weeks.

Control group: Transcranial Magnetic Stimulation with concentration on Mirror Neuron System for 30 minutes 5 times a week for 2 consecutive weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: major depressive disorder; age of 18 to 65 years; receiving standard anti-depression drugs. Exclusion criteria: pregnancy; drug abuse during the last month; drug addiction during the last six months; neurologic disease or convulsion; having metal implant; using lorazepam, benzodiazepines, monoamine oxidase enzyme inhibitors or bupropion in the last month.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Assessing excitement regulation. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: using excitement adequacy ranking scale.;Assessing mood regulation. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: using POMS criteria.;Assessing social perception. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: by reading mind in the eyes.	—

Measure

Time frame

Assessing excitement regulation. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: using excitement adequacy ranking scale.;Assessing mood regulation. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: using POMS criteria.;Assessing social perception. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: by reading mind in the eyes.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Taiebi

Farshchian Hospital

tayebi.ir@gmail.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026